These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36244310)

  • 1. Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins.
    Rani R; Long S; Pareek A; Dhaka P; Singh A; Kumar P; McInerney G; Tomar S
    Virology; 2022 Dec; 577():1-15. PubMed ID: 36244310
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Gurung AB
    Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.
    Freidel MR; Armen RS
    PLoS One; 2021; 16(2):e0246181. PubMed ID: 33596235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic and thermodynamic characterization of antiviral inhibitors targeting nucleocapsid N-terminal domain of SARS-CoV-2.
    Dhaka P; Singh A; Choudhary S; Peddinti RK; Kumar P; Sharma GK; Tomar S
    Arch Biochem Biophys; 2023 Dec; 750():109820. PubMed ID: 37956938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach.
    Romeo I; Ambrosio FA; Costa G; Corona A; Alkhatib M; Salpini R; Lemme S; Vergni D; Svicher V; Santoro MM; Tramontano E; Ceccherini-Silberstein F; Artese A; Alcaro S
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies.
    Kumar S; Sharma PP; Upadhyay C; Kempaiah P; Rathi B; Poonam
    Methods; 2021 Nov; 195():44-56. PubMed ID: 33639316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay.
    Chen GY; Pan YC; Wu TY; Yao TY; Wang WJ; Shen WJ; Ahmed A; Chan ST; Tang CH; Huang WC; Hung MC; Yang JC; Wu YC
    J Tradit Complement Med; 2022 Jan; 12(1):73-89. PubMed ID: 34549024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening.
    Samdani MN; Morshed N; Reza R; Asaduzzaman M; Islam ABMMK
    Mol Divers; 2023 Jun; 27(3):1067-1085. PubMed ID: 35690957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying polypharmacology approach for drug repurposing for SARS-CoV2.
    Jamir E; Sarma H; Priyadarsinee L; Nagamani S; Kiewhuo K; Gaur AS; Rawal RK; Murugan NA; Subramanian V; Sastry GN
    J Chem Sci (Bangalore); 2022; 134(2):57. PubMed ID: 35498548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic insights into bismuth(iii) inhibition of SARS-CoV-2 helicase.
    Wei X; Chan CL; Zhou Y; Tang K; Chen J; Wang S; Chan JF; Yuan S; Li H; Sun H
    Chem Sci; 2024 Jul; 15(26):10065-10072. PubMed ID: 38966375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity.
    Mohammad TSH; Gupta Y; Reidl CT; Nicolaescu V; Gula H; Durvasula R; Kempaiah P; Becker DP
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
    Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Silico Screening of Natural Products as Potential Inhibitors of SARS-CoV-2 Using Molecular Docking Simulation.
    Hossain R; Sarkar C; Hassan SMH; Khan RA; Arman M; Ray P; Islam MT; Daştan SD; Sharifi-Rad J; Almarhoon ZM; Martorell M; Setzer WN; Calina D
    Chin J Integr Med; 2022 Mar; 28(3):249-256. PubMed ID: 34913151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets.
    Yang T; Wang SC; Ye L; Maimaitiyiming Y; Naranmandura H
    Expert Opin Drug Discov; 2023 Mar; 18(3):247-268. PubMed ID: 36723288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).
    Dong S; Sun J; Mao Z; Wang L; Lu YL; Li J
    J Med Virol; 2020 Sep; 92(9):1542-1548. PubMed ID: 32181901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural interactions of phytoconstituent(s) from cinnamon, bay leaf, oregano, and parsley with SARS-CoV-2 nucleocapsid protein: A comparative assessment for development of potential antiviral nutraceuticals.
    Husain I; Ahmad R; Siddiqui S; Chandra A; Misra A; Srivastava A; Ahamad T; Khan MF; Siddiqi Z; Trivedi A; Upadhyay S; Gupta A; Srivastava AN; Ahmad B; Mehrotra S; Kant S; Mahdi AA; Mahdi F
    J Food Biochem; 2022 Oct; 46(10):e14262. PubMed ID: 35796388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent multi-target natural inhibitors against SARS-CoV-2 from medicinal plants of the Himalaya: a discovery from hybrid machine learning, chemoinformatics, and simulation assisted screening.
    Maiti P; Nand M; Mathpal S; Wahab S; Kuniyal JC; Sharma P; Joshi T; Ramakrishnan MA; Chandra S
    J Biomol Struct Dyn; 2023 Sep; ():1-14. PubMed ID: 37732349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.
    Sabarimurugan S; Dharmarajan A; Warrier S; Subramanian M; Swaminathan R
    Ann Transl Med; 2020 Oct; 8(19):1247. PubMed ID: 33178779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.